Zhao Ying et al. [20] investigated the cognitive and metabolic benefits of dapagliflozin in elderly patients with diabetes and mild cognitive impairment, while Mone et al. [24] conducted a similar analysis on patients with diabetes and concomitant heart failure, also evaluating differences with insulin and metformin therapy. This evidence concerns the gene INS and Cognitive impairment.